Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms

The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib. A better understanding of cellular changes induced by ruxolitinib is required to develop new combinato...

Descripción completa

Detalles Bibliográficos
Autores principales: Courdy, Charly, Platteeuw, Loïc, Ducau, Charlotte, De Araujo, Isabelle, Boet, Emeline, Sahal, Ambrine, Saland, Estelle, Edmond, Valérie, Tavitian, Suzanne, Bertoli, Sarah, Cougoul, Pierre, Granat, Fanny, Poillet, Laura, Marty, Caroline, Plo, Isabelle, Sarry, Jean-Emmanuel, Manenti, Stéphane, Mansat-De Mas, Véronique, Joffre, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330179/
https://www.ncbi.nlm.nih.gov/pubmed/37423955
http://dx.doi.org/10.1038/s41408-023-00875-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330179/
https://www.ncbi.nlm.nih.gov/pubmed/37423955
http://dx.doi.org/10.1038/s41408-023-00875-x

Ejemplares similares